Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy

NCT04619082 is registered in ClinicalTrials.gov with Chiayi Christian Hospital as lead sponsor.

NCT NCT04619082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04619082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy
Lead sponsor
Chiayi Christian Hospital
Phase
Phase 4
Overall status
Active, not recruiting
Start date
July 1, 2021
Completion date
December 31, 2024
Enrollment
102 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b reactivation